CN102232942A - Antrodia camphorata cyclohexenone compound for suppressing growth of lymphoma tumor cells - Google Patents
Antrodia camphorata cyclohexenone compound for suppressing growth of lymphoma tumor cells Download PDFInfo
- Publication number
- CN102232942A CN102232942A CN 201010174717 CN201010174717A CN102232942A CN 102232942 A CN102232942 A CN 102232942A CN 201010174717 CN201010174717 CN 201010174717 CN 201010174717 A CN201010174717 A CN 201010174717A CN 102232942 A CN102232942 A CN 102232942A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- antrodia camphorata
- medical composition
- methyl
- dimethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a new use of a compound. In the invention, (4-hydroxy-2,3-dimethoxy-6-methy-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone is obtained from extract of Antrodia camphorata by separation and purification, and the cyclohexenone compound can be used for suppressing the growth of lymphoma tumor cells and can also be used in medical composition for suppressing the growth of the lymphoma tumor cells.
Description
Technical field
The invention relates to a kind of new application of chemical compound, especially about a kind of purposes that suppresses the lymphatic cancer growth of tumour cell by the chemical compound of institute's separation and purification in Antrodia Camphorata (Antrodia cinnamomea) extract of utilizing.
Background technology
After the lymphocyte that is characterized as normal configuration of lymphatic cancer (Lymphoma) is damaged, replace jejune lymph corpuscle.Lymphatic cancer is the good malignant tumor (malignant tumor) that comprises lymphocyte, lymphatic vessel and lymph gland in the body endolymphatic system of sending out; On the other hand, be responsible for the lymphocyte of lymphocytic manufacturing, storage and the differentiation division of labor and regulate the pathological changes that organ comprises bone marrow, spleen and thymus, also can bring out lymphatic cancer.Clinically often according to the difference of tumor pathology organizational patterns with lymphatic cancer why divide outstanding Jin Shi lymphatic cancer (Hodgkin ' sdisease) and two kinds of Fei Hejiejinshi lymphatic cancers (Non-Hodgkin ' s lymphoma), wherein common with the Fei Hejiejinshi lymphatic cancer again.
The possible cause that lymphatic cancer takes place comprises the use of immune disappearance, viral infection, lonizing radiation or medicine and heredity etc.Research points out that lymphatic cancer is very average in the sickness rate of each age level, and men and women's number of the infected ratio is equal approximately, lymphatic cancer is the most normal with lymphadenopathy early symptom greatly, especially good in the lymph node at positions such as cervical region, oxter or groin, and often be the lymph node enlargement of painless property bunchiness, the general symptom can appear in some patient, as fever, Sleep hyperhidrosis, lose weight, long-term taediumvitae or powerlessness, skin are itched signs such as dermexanthesis; In addition, the first morbidity kitchen range of 1/3rd lymphatic cancers of having an appointment is at lymph gland, and betides internal organs, and as vertical diaphragm chamber of stomach, intestine and small intestine, lung etc., its symptom comprises stomachache, gastrorrhagia, intestinal obstruction or pulmonary's dyspnea etc.
The treatment of lymphatic cancer is different according to its cancer pathology kenel and clinical stages; treat main mode and comprise radiation cure, chemotherapy and bone marrow transplantation or peripheral blood stem cell transplantation etc.; generally speaking; lower and the patient that belongs to initial stage regional nodes's cancer of grade of malignancy; be fit to carry out radiation cure; and grade of malignancy is high and belong to the patient of middle and advanced stage; due to illness feelings worsen very fast; and scatter whole body easily; so based on chemotherapy; no matter yet be radiation cure or chemotherapy, regular meeting causes many side effect or malaise symptoms.Therefore, if can find the effectively natural therapeutant that has no side effect, must more promote lymphatic cancer treatment effect and other malaise symptoms of avoiding deriving.
Antrodia Camphorata (Antrodia cinnamomea), among the peoplely in Taiwan be called wild rice, Antrodia camphorata or red Camphor tree in Camphor tree mushroom, Camphor tree wild rice, the Camphor tree again, be the exclusive medicinal mushrooms of this province, it belongs to the perennial mushroom fungus class of Aphyllophorales (Aphyllophorales), Polyporaceae (Polyporaceae).Because Antrodia camphorata only parasitizes on the dried hollow heartwood interior wall tissue of Taiwan distinctive child care class Cinnamomum kanahirai hay ebon at occurring in nature, add artificial felling trees unlawfully, make and to parasitize more shape rareness of the wild Antrodia Camphorata quantity that wherein can grow, and since under naturalness the growth phase of Antrodia camphorata sporophore when slowly, so wild Antrodia camphorata quantity is rare and cost an arm and a leg.
The sporophore of Antrodia Camphorata is perennial, and stockless is suberin to wooden, and the intensive Lignum cinnamomi camphorae fragrance of its tool, and changeableization of form have tabular, mitriform, horse-hof shape or tower shape.Nascent is platypelloid type and is cerise that its periphery can present radiation warp shape afterwards, and to expansion growth all around, color also changes light red brown or khaki into, and many pores are arranged, and it is the abundantest position of medical value of Antrodia Camphorata.
In the Taiwan folk custom medically, Antrodia Camphorata has that the circulation of qi promoting of dispeling the wind, blood stasis dispelling are invigorated blood circulation, the effect of warming middle-JIAO removing food stagnancy, removing toxic substances and promoting subsidence of swelling and sedation-analgesia, and be considered as first-class antidote, all alimentary toxicosis, diarrhoea, vomiting, pesticide intoxication all has Detoxication, all has the auxiliary treatment effect to improving liver, stomach malfunction and blood circulation disease in addition.Antrodia Camphorata is as the gill fungus mushrooms of edible medicinal, composition with many complexity, in the known physiologically active ingredient, comprise: triterpenoid compound (triterpenoids), polysaccharide body (polysaccharides, as callose), adenosine (adenosine), vitamin is (as vitamin B, niacin), protein (containing immunoglobulin), sudismase (superoxide dismutase, SOD), trace element (as: calcium, phosphorus, germanium), nucleic acid, steroid and blood pressure stabilization material (as antodia acid) etc., these a little physiologically active ingredients are considered to have antitumor, increase immunocompetence, antiallergic, disease-resistant bacterium, resisting hypertension, multiple efficacies such as blood sugar lowering and cholesterol reducing, and help the treatment of hepatoprotective and liver related disease.
The composition Study of relevant Antrodia camphorata, focus on macromolecular polysaccharide body (polysaccharides) and micromolecular triterpenes (triterpenoids) and steroid (steroids) mostly, wherein, Antrodia camphorata contains macromolecular polysaccharide body, form with different monosaccharide and to be present in its sporophore and the mycelium, but after spectrum analysis, all contain the callose (β-D-glucans) of tool physiologically active; Triterpenoid compound is the general name that is combined into hexagon or pentagon native compound by 30 carbons, and the bitterness of Antrodia Camphorata institute tool is promptly mainly from this composition of triterpenes, and it also is to be studied maximum compositions.The triterpenoid compound that obtains from sporophore has antrocin, 4,7-dimethoxy-5-methyl isophthalic acid, 3-benzo dioxy ring (4,7-dimethoxy-5-methy-1,3-benzodioxole) and 2,2 ', 5,5 '-tetramethoxy-3,4,3 ', 4 '-two-methylene-dioxy-6,6 '-dimethyl diphenyl (2,2 ', 5,5 '-teramethoxy-3,4,3 ', 4 '-bi-methylenedioxy-6,6 '-dimethyl biphenyl) (Chiang et al., 1995), be the new triterpenoid compound antcinA of skeleton with lumistane (ergostane), antcin B, antcin C antcin E, antcin F, methyl antcinate G and methyl antcinateH (Cherng et al., 1995,1996).It is that the chemical compound of skeleton comprises Zhankuic acid A, B and C zhankuic acid D and zhankuic acid E (Chen and Yang, 1995 that sporophore contains in addition with the lumistane; Yang 1996), be noval chemical compound 15 α-acetyl-dehydrogenation sulfurenic acid (15 α-acetyl-dehydrosulphurenic acid), the dehydrogenation eburicoic acid (dehydroeburicoic acid) of skeleton and the sulfurenic acid (dehydrasulphurenic acid) that anhydrates with lanostane (lanostane).
Though can learn that by many experiments at present the Antrodia Camphorata extract has aforementioned effect, and its ingredient is also analyzed successively to be gone out, but which kind of effective ingredient in the extract can be facilitated the inhibition cancer effect of Antrodia Camphorata actually, do not deliver concrete relevant effective ingredient, remaining further experiment research differentiates, so if can find out the contained real composition that effectively suppresses tumor growth in this extract, to help Antrodia Camphorata and press down the research that cancer is shut down mutually changes, and Antrodia Camphorata is applied to cancer, and for example the treatment and the prevention of lymphatic cancer there are greatest help.
Summary of the invention
For understanding in the Antrodia Camphorata extract is that what composition has the effect that presses down cancer actually, and the present invention provides the chemical compound of following structural (1) by separation and purification in the Antrodia Camphorata extract;
Wherein, X is oxygen (O) or sulfur (S), and Y is oxygen or sulfur; R1 is hydrogen base (H), methyl (CH
3) or (CH
2) m-CH
3, R
2Be hydrogen base, methyl or (CH
2) m-CH
3, R
3Be hydrogen base, methyl or (CH
2) m-CH
3, m=1～12; N=1～12.
In the chemical compound suc as formula (1) structural formula, the preferably is the chemical compound of formula as follows (2):
The chemical compound of formula (2), its chemistry 4-hydroxyl-2 by name, 3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene (4-hydroxy-2,3-dimethoxy-6-methy-5 (3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone), molecular formula is C
24H
38O
4, outward appearance is the pale yellow powder shape, molecular weight is 390.
The chemical compound of Chinese style of the present invention (1), formula (2) is that separation and purification is from Antrodia Camphorata water extract or organic solvent extraction thing, organic solvent can comprise alcohols (for example methanol, ethanol or propanol), esters (for example ethyl acetate), alkanes (for example hexane) or alkyl halide (for example chloromethanes, ethyl chloride), but not as limit, wherein the preferably is an alcohols, and better person is an ethanol.
By aforesaid compound, the present invention is applied to suppress on the growth of tumour cell, enables further to use the medicine that is included in the treatment cancer and forms in part, gain treatment for cancer effect.The scope that the present invention must use this chemical compound comprises the growth inhibited for the lymphatic cancer tumor cell, by suppressing the ramp of these tumor cells, and then suppresses the hypertrophy of tumor, and delays the deterioration of tumor.Wherein, preferable chemical compound is the 4-hydroxyl-2 of formula (2), 3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene.
On the other hand, also the chemical compound of formula (1) or/and formula (2) can be used among the present invention in the composition of the medical composition that suppresses the lymphatic cancer growth of tumour cell.Aforementioned medical composition still can comprise pharmaceutically acceptable carrier except that the chemical compound of formula that comprises effective dose (1) or/and formula (2).Carrier can be excipient (as water), filler (as sucrose or starch), adhesive (as cellulose derivative), diluent, disintegrating agent, absorption enhancer or sweeting agent, but does not only limit to this.Medical composition of the present invention can be manufactured according to the preparation method of general known pharmacy, with formula (1) or/mix mutually with more than one carrier with formula (2) effective ingredient dosage, prepare required dosage form, this dosage form can comprise lozenge, powder, granule, capsule or other liquid preparation, but not as limit.
Below will further specify embodiments of the present invention; following cited embodiment is in order to illustrate the present invention; be not in order to limit scope of the present invention; anyly have the knack of this skill person; without departing from the spirit and scope of the present invention; when can doing a little change and retouching, so protection scope of the present invention is as the criterion when looking the accompanying Claim person of defining.
The specific embodiment
Through extraction Antrodia Camphorata water extract or organic solvent extraction thing later, can be further by in addition separation and purification of high performance liquid chroma-tography, again each separatory (fraction) is carried out the test of cancer resistant effect afterwards.At last, then the separatory at the tool cancer resistant effect carries out component analysis, and the composition that may produce cancer resistant effect is further done the inhibition measure of merit of lymphatic cancer tumor cell respectively.Find promptly that finally the chemical compound suc as formula (1)/formula (2) has the effect that suppresses the lymphatic cancer growth of tumour cell among the present invention.
The present invention for convenience of description below will be with the 4-hydroxyl-2 of formula (2), and 3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene chemical compound describes.In addition, for confirming 4-hydroxyl-2,3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene chemical compound is to the inhibition effect of growth of tumour cell, is with the MTT analytic process among the present invention, according to American National ICR (National Cancer Institute, NCI) antitumor drug screening pattern is carried out the test of cell survival rate to the lymphatic cancer tumor cell.Confirm 4-hydroxyl-2,3-dimethoxy-6-methyl-5 (3 by those tests, 7,11-trimethyl-2,6,10-12 carbon triolefins)-the 2-cyclonene is for the lymphatic cancer tumor cell: U937 cell line can reduce its survival rate, relatively under and can to reduce growth half suppression ratio desired concn simultaneously (be IC
50Value), therefore must be by 4-hydroxyl-2,3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene is applied on the growth inhibited of lymphatic cancer tumor cell, and further can be used in the treatment of lymphatic cancer.Now aforementioned embodiments is elaborated as follows:
Embodiment 1:
4-hydroxyl-2, the separation of 3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene
With Antrodia Camphorata mycelium, sporophore or the mixture of the two about 100 grams, insert in the triangular pyramidal bottle, the water and the alcohols (70%～100% alcohol solution) that add proper proportion, wherein, described alcohols is preferably ethanol, the stirring extraction is more than at least 1 hour down in 20～25 ℃, and afterwards with filter paper and 0.45 μ m membrane filtration, collection filtrate promptly gets the Antrodia Camphorata extract.
Antrodia Camphorata extract with aforementioned collection, utilize high-effect liquid chromatography (LC) instrument (High PerformanceLiquid chromatography), chromatography pipe (column) with RP18 is analyzed, and with methanol (A) and 0.1%～0.5% aqueous acetic acid (B) (its solution proportion is: 0～10 minute, the B ratio was 95%～20% as mobile phase (mobile phase); 10～20 minutes, the B ratio was 20%～10%; 20～35 minutes, the B ratio was 10%～90%; 35～40 minutes, the B ratio was 10%～95%), under the speed of per minute 1ml, dash and carry, simultaneously with the long detector analysis of ultraviolet-visible light all-wave.
With 25 minutes to 30 minutes dash extract collect to concentrate get final product the solid product of pale yellow powder shape, this is a 4-hydroxyl-2,3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene.By analysis, its molecular formula is C
24H
38O
4, molecular weight 390, fusing point (m.p.) are 48 ℃～52 ℃.Nuclear magnetic resonance, NMR (NMR) assay value is then as follows:
1H-NMR (CDCl
3) δ (ppm): 1.51,1.67,1.71,1.75,1.94,2.03,2.07,2.22,2.25,3.68,4.05,5.07 and 5.14.
13C-NMR (CDCl
3) δ (ppm): 12.31,16.1,16.12,17.67,25.67,26.44,26.74,27.00,39.71,39.81,4.027,43.34,59.22,60.59,120.97,123.84,124.30,131.32,135.35,135.92,138.05,160.45 and 197.12.
Embodiment 2:
External antiangiogenic tumor cell activity test
By in the further test implementation example 1 the discovery chemical compound to the inhibition effect of tumor cell, present embodiment will be according to American National ICR (National Cancer Institute, NCI) antitumor drug screening pattern, at first get isolating 4-hydroxyl-2 among the embodiment 1,3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene chemical compound, add and contain in the culture fluid of human lymphatic cancer tumor cell U937, carry out the test of tumor cell viability.Wherein, the test of cell survival can be adopted known MTT analytic process and be analyzed, and lymphatic cancer tumor cell U937 is human lymphocytic cancer cell strain (human histiocytic lymphoma cell line).
The MTT analytic process is a kind of common analytical method that is used for analysis of cells hypertrophy (cell proliferation), survival rate (percent of viable cells) and cytotoxicity (cytotoxicity).Wherein, MTT (3-[4,5-dimethylthiazol-2-yl] 2,5-diphenyltetrazolium bromide) is a yellow stain, it can be absorbed by living cells and is reduced into water insoluble by the succinic acid tetrazolium reductase (succinate tetrazoliumreductase) in the Mitochondria and be hepatic formazan, therefore whether form by formazan, can judge and calculate the survival rate of cell.
At first human lymphocytic cancer cell U937 is cultivated in the RPMI1640 culture medium that contains 10% hyclone (fetal bovine serum), this culture medium still comprises the dish Ni Xilin (Penicillin) of 10U/ml, and the streptomycin (Streptomycin) of 100 μ g/ml, and in 5%CO
2, cultivated 24 hours in 37 ℃ of environment.Cell after the hypertrophy is cleaned once with PBS, and handle cell with trypsin-EDTA of 1 times, subsequently in 1, under the 200rpm centrifugal 5 minutes, with cell precipitation and abandon supernatant.Add the new culture fluid of 10ml afterwards, slight wobble suspends cell once more, in the 96 holes trace dish that again cell is placed in.During test, organize (without total extract of purifies and separates) in contrast respectively at the Antrodia Camphorata extract that adds 30,10,3,1,0.3,0.1 and 0.03 μ g/ml in each hole; And the 4-hydroxyl-2 that in each hole, adds 30,10,3,1,0.3,0.1 and 0.03 μ g/ml, 3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene is as test group, in 37 ℃, 5%CO
2Under cultivated 48 hours.Thereafter, the MTT in add 2.5mg/ml under the environment of lucifuge in each hole reacts the lysis buffer cessation reaction that adds 100 μ l after 4 hours again in each hole.Under 570nm extinction wavelength, measure its light absorption value with Enzyme Immunoassay Analyzer at last, use the survival rate of calculating cell, and to extrapolate its half suppression ratio desired concn of growing (be IC
50Value), its result as shown in Table 1.
Table one: external test result to lymphatic cancer tumor cell survival rate
By in the table one as can be known, by 4-hydroxyl-2, the effect of 3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene, it is for the IC of the human lymphatic cancer tumor cell of U937
50Value is 9.71 μ g/ml, compared to the measured IC of matched group Antrodia Camphorata extraction mixture
50Value (not showing in the table) is low many, so the 4-hydroxyl-2 in the susceptible of proof Antrodia Camphorata extract, 3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-the 2-cyclonene can be used in the inhibition of lymphatic cancer growth of tumour cell really.
In sum, the 4-hydroxyl-2 of separated from Antrodia camphorate of the present invention, 3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene chemical compound can effectively suppress the growth of lymphatic cancer tumor cell.On the other hand, because of the Cinnamomum kanahirai hay pimelie kelone compound is the material of natural extraction, when so it is applied to suppress lymphatic cancer, can't cause other side effect such as patient's discomfort or toxigenicity, complication etc., and its also can with chemotherapeutic agents and usefulness, to reduce the chemotherapeutics using dosage and to reduce the side effect that those chemotherapeutic agents are caused; In addition, also it can be prepared into the medical composition of treatment lymphatic cancer, wherein, this medical composition still can comprise pharmaceutically acceptable carrier except that the Cinnamomum kanahirai hay pimelie kelone compound that comprises effective dose.Carrier can be excipient (as water), filler (as sucrose or starch), adhesive (as cellulose derivative), diluent, disintegrating agent, absorption enhancer or sweeting agent, but does not only limit to this.Medical composition of the present invention can be manufactured according to the preparation method of general known pharmacy, the Cinnamomum kanahirai hay pimelie kelone compound of effective ingredient dosage is mixed mutually with more than one carrier, prepare required dosage form, this dosage form can comprise lozenge, powder, granule, capsule or other liquid preparation, but not as limit.Use the purpose that reaches treatment lymphatic cancer tumor disease.
Claims (16)
1. the chemical compound that will have following structural is used in the application that preparation suppresses the medicine of lymphatic cancer growth of tumour cell:
Wherein, X is oxygen (O) or sulfur (S), and Y is oxygen or sulfur; R
1Be hydrogen base (H), methyl (CH
3) or (CH
2)
m-CH
3, R
2Be hydrogen base, methyl or (CH
2)
m-CH
3, R
3Be hydrogen base, methyl or (CH
2)
m-CH
3, m=1～12; N=1～12.
2. application according to claim 1, wherein, described chemical compound is a 4-hydroxyl-2,3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene (4-hydroxy-2,3-dimethoxy-6-methy-5 (3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone).
3. application according to claim 2, wherein, described chemical compound is separated by the Antrodia Camphorata extract to be made.
4. application according to claim 3, wherein, described chemical compound is separated by the water extract of Antrodia Camphorata to be made.
5. application according to claim 3, wherein, described chemical compound is separated by the organic solvent extraction thing of Antrodia Camphorata to be made.
6. application according to claim 5, wherein, described organic solvent is selected from the group that esters, alcohols, alkanes and alkyl halide form.
7. application according to claim 6, wherein, described alcohols is an ethanol.
8. application according to claim 1, wherein, described lymphatic cancer tumor cell is a U937 cell line.
9. a medical composition that is used to suppress the lymphatic cancer growth of tumour cell comprises effective dose chemical compound according to claim 1 and pharmaceutically acceptable carrier.
10. medical composition according to claim 9, wherein, described chemical compound is a 4-hydroxyl-2,3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-12 carbon triolefins)-2-cyclonene (4-hydroxy-2,3-dimethoxy-6-methy-5 (3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone).
11. medical composition according to claim 10, wherein, described chemical compound is separated by the Antrodia Camphorata extract to be made.
12. medical composition according to claim 11, wherein, described chemical compound is separated by the water extract of Antrodia Camphorata to be made.
13. medical composition according to claim 11, wherein, described chemical compound is separated by the organic solvent extraction thing of Antrodia Camphorata to be made.
14. medical composition according to claim 13, wherein, described organic solvent is selected from the group that esters, alcohols, alkanes and alkyl halide form.
15. medical composition according to claim 14, wherein, described alcohols is an ethanol.
16. medical composition according to claim 9, wherein, described lymphatic cancer tumor cell is a U937 cell line.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010174717 CN102232942B (en) | 2010-05-06 | 2010-05-06 | Antrodia camphorata cyclohexenone compound for suppressing growth of lymphoma tumor cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010174717 CN102232942B (en) | 2010-05-06 | 2010-05-06 | Antrodia camphorata cyclohexenone compound for suppressing growth of lymphoma tumor cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102232942A true CN102232942A (en) | 2011-11-09 |
| CN102232942B CN102232942B (en) | 2013-03-27 |
Family
ID=44884367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010174717 Active CN102232942B (en) | 2010-05-06 | 2010-05-06 | Antrodia camphorata cyclohexenone compound for suppressing growth of lymphoma tumor cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102232942B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105246470A (en) * | 2013-02-20 | 2016-01-13 | 国鼎生物科技股份有限公司 | Methods and compositions for treating leukemia |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101225066A (en) * | 2007-01-18 | 2008-07-23 | 国鼎生物科技股份有限公司 | Cyclohexenone extract of antrodia camphorata |
| CN101357883A (en) * | 2007-07-30 | 2009-02-04 | 国鼎生物科技股份有限公司 | Antrodia camphoratea pimelie kelone compound for treating autoimmune disease and medicine composition |
-
2010
- 2010-05-06 CN CN 201010174717 patent/CN102232942B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101225066A (en) * | 2007-01-18 | 2008-07-23 | 国鼎生物科技股份有限公司 | Cyclohexenone extract of antrodia camphorata |
| CN101357883A (en) * | 2007-07-30 | 2009-02-04 | 国鼎生物科技股份有限公司 | Antrodia camphoratea pimelie kelone compound for treating autoimmune disease and medicine composition |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105246470A (en) * | 2013-02-20 | 2016-01-13 | 国鼎生物科技股份有限公司 | Methods and compositions for treating leukemia |
| JP2016509058A (en) * | 2013-02-20 | 2016-03-24 | ゴールデン バイオテクノロジー コーポレーション | Methods and compositions for treating leukemia |
| CN108309961A (en) * | 2013-02-20 | 2018-07-24 | 国鼎生物科技股份有限公司 | method and composition for treating leukaemia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102232942B (en) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101417934B (en) | New compounds separated from Antrodia camphorate extract | |
| TWI335314B (en) | ||
| JP5085186B2 (en) | A novel compound isolated from Benix nokitake | |
| CN101225066B (en) | Cyclohexenone extract of antrodia camphorata | |
| TWI394566B (en) | Used to inhibit the growth of ovarian cancer tumor cells of the cattle camphor cyclohexene ketone compounds | |
| CN101214238B (en) | Application of Antrodia camphorata extract for inhibiting tumor cell growth | |
| TW201102075A (en) | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of pancreatic cancer | |
| CN102000046B (en) | Application of antrodia camphorata cyclohexenone compound in preparing medicine for inhibiting growth of pancreatic cancer tumor cells | |
| CN102000047B (en) | Antrodia camphorata cyclonene compound for restraining growth of bone cancer cells | |
| TWI383791B (en) | Used to inhibit the growth of gastric cancer tumor cells of the male antler ketone compounds | |
| CN101343247B (en) | Cyclohexenone extract of antrodia camphorata | |
| CN104177240B (en) | The compound of separated from Antrodia sesame, extract and application thereof | |
| TW201109023A (en) | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of colorectal cancer | |
| CN102232942B (en) | Antrodia camphorata cyclohexenone compound for suppressing growth of lymphoma tumor cells | |
| TWI379678B (en) | ||
| TW201102076A (en) | Cyclohexenone compound of Antrodia cinnomomea suppressing growth of tumor cell of osteosarcoma | |
| CN103408528B (en) | Chroman compound, as well as preparation method and application thereof | |
| TWI379679B (en) | ||
| CN102232943B (en) | Antrodia camphorata cyclohexenone compound for inhibiting skin cancer tumor cell growth | |
| CN102232941B (en) | Antrodia camphorata cyclohexenone compound for inhibiting ovarian cancer tumor cell growth | |
| CN102232945B (en) | Antrodia camphorata cyclohexenone compound for suppressing growth of bladder cancer tumor cells | |
| CN102232940B (en) | Antrodia camphorata cyclohexenone compound for inhibiting colorectal cancer tumor cell growth | |
| CN102232946B (en) | Use of antrodia camphorata cyclohexenone compound in preparing medicine for inhibiting stomach cancer tumor cell growth | |
| TW201034657A (en) | Cyclohexene compound | |
| TW201109024A (en) | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of bladder cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |